{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Go AS"],"funding":["NCATS NIH HHS","NIDDK NIH HHS","NIA NIH HHS","AHRQ HHS","NHLBI NIH HHS","FDA HHS","NINDS NIH HHS"],"pagination":["e75-e85"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9995163"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["54(3)"],"pubmed_abstract":["Atrial fibrillation (AF) is one of the strongest risk factors for ischemic stroke, which is a leading cause of disability and death. Given the aging population, increasing prevalence of AF risk factors, and improved survival in those with cardiovascular disease, the number of individuals affected by AF will continue increasing over time. While multiple proven stroke prevention therapies exist, important questions remain about the optimal approach to stroke prevention at the population and individual patient levels. Our report summarizes the National Heart, Lung, and Blood Institute virtual workshop focused on identifying key research opportunities related to stroke prevention in AF. The workshop reviewed major knowledge gaps and identified targeted research opportunities to advance stroke "],"journal":["Stroke"],"pubmed_title":["Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop."],"pmcid":["PMC9995163"],"funding_grant_id":["R21 AG067463","R01 NS121419","U01 FD006292","R01 HL092577","UL1 TR001863","R01 HL131535","R56 HL142765","R01 AG066010","K24 HL141354","R01 DK103612","R01 DK095024","R01 AG066914","R01 AG062436","R01 HS025402","R01 HL141434","R01 HL128914","R01 HL142765","R01 HL142834"],"pubmed_authors":["Hanke T","Al-Khatib SM","True Hills M","Bushnell CD","Cooper LS","Desvigne-Nickens P","Reddy VY","Go AS","Thomas KL","Turakhia MP","Fang MC","Hylek EM","Gage BF","Noseworthy PA","Lopes RD","Freeman JV","Singer DE","Zieman SJ","Bansal N","Benjamin EJ"],"additional_accession":[]},"is_claimable":false,"name":"Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.","description":"Atrial fibrillation (AF) is one of the strongest risk factors for ischemic stroke, which is a leading cause of disability and death. Given the aging population, increasing prevalence of AF risk factors, and improved survival in those with cardiovascular disease, the number of individuals affected by AF will continue increasing over time. While multiple proven stroke prevention therapies exist, important questions remain about the optimal approach to stroke prevention at the population and individual patient levels. Our report summarizes the National Heart, Lung, and Blood Institute virtual workshop focused on identifying key research opportunities related to stroke prevention in AF. The workshop reviewed major knowledge gaps and identified targeted research opportunities to advance stroke ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-06-01T17:22:27.26Z","creation":"2025-04-03T23:50:11.957Z"},"accession":"S-EPMC9995163","cross_references":{"pubmed":["36848427"],"doi":["10.1161/STROKEAHA.121.038273","10.1161/strokeaha.121.038273"]}}